Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis
- PMID: 27775177
- DOI: 10.1002/ardp.201600186
Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis
Abstract
Mycobacterium tuberculosis enoyl-ACP reductase (InhA) has been validated as a promising target for antitubercular agents. Isoniazid (INH), the most prescribed drug to treat tuberculosis (TB), inhibits a NADH-dependent InhA that provides precursors of mycolic acids, which are components of the mycobacterial cell wall. It is a pro-drug that needs activation to form the inhibitory INH-NAD adduct by KatG coding for catalase-peroxidase. The INH resistance of M. tuberculosis is caused by mutations in KatG, which may lead to multidrug-resistant TB (MDR-TB). Hence, there is a need for new drugs that can combat MDR-TB. The rationale for the development of new drugs to combat MDR-TB strains is the design of InhA inhibitors that can bypass bioactivation by KatG. In the present review, special attention was paid to discuss the chemical nature and recent developments of direct InhA inhibitors. The InhA inhibitors reported here have significant inhibitory effects against Mtb InhA. The diphenyl ether derivatives have shown slow onset, a tight-binding mechanism, and high affinity at the InhA active site. However, some of the diphenyl ethers have significant in vitro efficacy, which fails to transform into in vivo efficacy. Among the InhA inhibitors, 4-hydroxy-2-pyridones have emerged as a new chemical class with significant InhA inhibitory activity and better pharmacokinetic parameters when compared to diphenyl ethers.
Keywords: 4-Hydroxy-2-pyridones; Antituberculosis activity; Aryl amides; Diphenyl ethers; Mtb InhA.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.J Biol Chem. 2010 May 7;285(19):14330-7. doi: 10.1074/jbc.M109.090373. Epub 2010 Mar 3. J Biol Chem. 2010. PMID: 20200152 Free PMC article.
-
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13881-6. doi: 10.1073/pnas.2235848100. Epub 2003 Nov 17. Proc Natl Acad Sci U S A. 2003. PMID: 14623976 Free PMC article.
-
Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis.Mini Rev Med Chem. 2010 Mar;10(3):181-92. doi: 10.2174/138955710791185064. Mini Rev Med Chem. 2010. PMID: 20408801 Review.
-
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.Curr Pharm Des. 2006;12(19):2409-24. doi: 10.2174/138161206777698927. Curr Pharm Des. 2006. PMID: 16842188 Review.
-
Direct inhibitors of InhA are active against Mycobacterium tuberculosis.Sci Transl Med. 2015 Jan 7;7(269):269ra3. doi: 10.1126/scitranslmed.3010597. Sci Transl Med. 2015. PMID: 25568071 Free PMC article.
Cited by
-
Biological and Biochemical Evaluation of Isatin-Isoniazid Hybrids as Bactericidal Candidates against Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0001121. doi: 10.1128/AAC.00011-21. Epub 2021 Jul 16. Antimicrob Agents Chemother. 2021. PMID: 33972252 Free PMC article.
-
Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.Biomed Res Int. 2022 Feb 25;2022:5099312. doi: 10.1155/2022/5099312. eCollection 2022. Biomed Res Int. 2022. PMID: 35252448 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
